Faculty profile

Eshrak Al-Shaibani

Back to faculty

Assistant ProfessorDepartment of MedicineUniversity of Toronto

Eshrak Al-Shaibani

Assistant Professor

Department of Medicine

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
19 publications in the last five years, latest in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

107

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
British journal of haematology · 2026
Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy · 2026
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.
JCO oncology practice · 2026

All 19 publications

19 publications.

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Desai N, Althobaiti M, Chen C, Al-Shaibani E, Moya TA, Novitzky-Basso I, Pasic I, Michelis FV, Kim DD, Kumar R, Mattsson J, Law AD, Viswabandya A

British journal of haematology20263 citations

DOI: 10.1111/bjh.70380 PMID: 41747740

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Rodriguez-Rodriguez S, Salas MQ, Desai N, Al-Shaibani E, Novitzky-Basso I, Pasic I, Viswabandya A, Michelis FV, Mattsson J, Kim DDH, Kumar R, Moya TA

Transplantation and cellular therapy20261 citations

DOI: 10.1016/j.jtct.2026.01.026 PMID: 41571188

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Desai N, Rodriguez-Rodriguez S, Chen C, Al-Shaibani E, Alfaro Moya T, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DDH, Kumar R, Mattsson J, Law AD

JCO oncology practice20261 citations

DOI: 10.1200/op-25-01308 PMID: 42372210

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Chiarello C, Singhabahu S, Remberger M, Chen C, Moya TA, Al-Shaibani E, Gerbitz A, Kim DDH, Kumar R, Lam W, Law AD, Lipton JH, Michelis FV, Novitzky-Basso I, Viswabandya A, Mattsson J, Pasic I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2025.10.002 PMID: 41062023

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.05.018 PMID: 42142626

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

Rodriguez-Rodriguez S, Chiarello C, Desai N, Remberger M, Chen C, Al-Shaibani E, Alfaro Moya T, Law AD, Pasic I, Viswabandya A, Michelis FV, Kim DDH, Kumar R, Mattsson J, Novitzky-Basso I

Transplantation and cellular therapy2026

DOI: 10.1016/j.jtct.2026.03.015 PMID: 41839367

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.

Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Kumar R, Kim DDH, Lipton JH, Mattsson J, Law AD

Blood advances202539 citationsOpen Access

DOI: 10.1182/bloodadvances.2024014781 PMID: 39565954

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms.

Desai N, Rodriguez-Rodriguez S, Chen C, Moya TA, Al-Shaibani E, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim D, Kumar R, Mattsson J, Law AD

European journal of haematology202510 citationsOpen Access

DOI: 10.1111/ejh.14430 PMID: 40337996

A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.

Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, Pasic I, Michelis FV, Kumar R, Kim DDH, Mattsson J, Viswabandya A

British journal of haematology20257 citations

DOI: 10.1111/bjh.70124 PMID: 40859738

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation.

Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Remberger M, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV

British journal of haematology20255 citationsOpen Access

DOI: 10.1111/bjh.70006 PMID: 40682490

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Eshrak Al-Shaibani

Research

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms.

A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation.

Frequent collaborators

Igor Novitzky-Basso

Auro Viswabandya

Ivan Pasic

Rajat Kumar

Jonas Mattsson

Tommy Moya

Tommy Alfaro Moya

Wilson Lam

Mohamed Elemary

Fotios Michelis

Dennis Kim

Christopher Lemieux

Shabbir Alibhai

Michael Kennah

Phedias Diamandis

Eshrak Al-Shaibani

Research

Latest papers

Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.

Frailty as a Prognostic Factor in Younger Adult Patients With Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

Size Does Not Always Matter: Limited Impact of Donor-recipient Weight Difference on Outcomes of Adult Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation.

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.

PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms.

A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell&#xa0;transplantation.

Frequent collaborators

Igor Novitzky-Basso

Auro Viswabandya

Ivan Pasic

Rajat Kumar

Jonas Mattsson

Tommy Moya

Tommy Alfaro Moya

Wilson Lam

Mohamed Elemary

Fotios Michelis

Dennis Kim

Christopher Lemieux

Shabbir Alibhai

Michael Kennah

Phedias Diamandis

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation.